Strongbridge Biopharma (SBBP) PT Set at $14.00 by Cantor Fitzgerald

Strongbridge Biopharma (NASDAQ:SBBP) has been given a $14.00 price target by research analysts at Cantor Fitzgerald in a research note issued to investors on Thursday. The firm presently has a “buy” rating on the biotechnology company’s stock. Cantor Fitzgerald’s price target would suggest a potential upside of 84.21% from the stock’s previous close.

A number of other research firms also recently weighed in on SBBP. BidaskClub raised shares of Strongbridge Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 11th. Zacks Investment Research downgraded shares of Strongbridge Biopharma from a “buy” rating to a “hold” rating in a research report on Wednesday, January 17th. Finally, HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Strongbridge Biopharma in a research report on Thursday, January 18th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $12.81.

How to Become a New Pot Stock Millionaire

NASDAQ:SBBP opened at $7.60 on Thursday. The company has a market cap of $386.83, a price-to-earnings ratio of -5.24 and a beta of 0.99. The company has a debt-to-equity ratio of -3.17, a current ratio of 4.88 and a quick ratio of 4.84. Strongbridge Biopharma has a fifty-two week low of $3.50 and a fifty-two week high of $9.25.

Strongbridge Biopharma (NASDAQ:SBBP) last released its earnings results on Monday, March 12th. The biotechnology company reported ($0.34) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.34). The firm had revenue of $2.98 million for the quarter, compared to analyst estimates of $2.98 million. sell-side analysts expect that Strongbridge Biopharma will post -1.52 EPS for the current year.

Several hedge funds have recently made changes to their positions in the company. 683 Capital Management LLC acquired a new stake in shares of Strongbridge Biopharma during the 4th quarter worth approximately $1,450,000. Lyon Street Capital LLC grew its position in shares of Strongbridge Biopharma by 239.0% during the 4th quarter. Lyon Street Capital LLC now owns 1,406,095 shares of the biotechnology company’s stock worth $10,194,000 after buying an additional 991,322 shares during the period. Paloma Partners Management Co acquired a new stake in shares of Strongbridge Biopharma during the 4th quarter worth approximately $152,000. Perceptive Advisors LLC acquired a new stake in shares of Strongbridge Biopharma during the 4th quarter worth approximately $1,994,000. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of Strongbridge Biopharma during the 4th quarter worth approximately $272,000. 57.63% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This article was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/07/strongbridge-biopharma-sbbp-pt-set-at-14-00-by-cantor-fitzgerald.html.

About Strongbridge Biopharma

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.

Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply